

In CAD with GI bleeding, higher mortality with triple therapy

December 6 2017



(HealthDay)—For patients with lower gastrointestinal bleeding (LGIB)

and coronary artery disease (CAD), triple therapy is associated with increased risk of mortality at 90 days after adjustment for confounding variables, according to a study published online Nov. 20 in the *Journal of Gastroenterology and Hepatology*.

Parita Patel, M.D., from the University of Chicago Medical Center, and colleagues conducted a [retrospective cohort study](#) involving 716 patients hospitalized with LGIB and CAD while on aspirin. Patients were identified using a validated algorithm and were classified by use of aspirin monotherapy (65.9 percent of patients); aspirin and thienopyridine (dual antiplatelet therapy [DAPT]; 25 percent); or aspirin, thienopyridine, and systemic anticoagulant ([triple therapy](#); 9.1 percent).

The researchers found that triple therapy was correlated with increased risk of 90-day and six-month mortality on univariate analysis (hazard ratios, 3.12 and 2.46, respectively). Holding anticoagulation was correlated with increased mortality at 90 days (hazard ratio, 2.3). Triple therapy remained associated with higher 90-day mortality after adjustment for confounding variables (hazard ratio, 3.23).

"The results of this study demonstrate higher comorbidity-adjusted 90-day and six-month mortality for those on triple therapy compared to those on aspirin monotherapy or DAPT. Our data additionally suggests that mortality may be driven by discontinuation of anticoagulation on discharge in patients initially treated with triple [therapy](#)," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: In CAD with GI bleeding, higher mortality with triple therapy (2017, December 6)
retrieved 23 April 2024 from

<https://medicalxpress.com/news/2017-12-cad-gi-higher-mortality-triple.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.